Oncology and Hematology

Episodes 49-64 of 72

• 

  RestartResume

  Current Unmet Needs in the Field of Unresectable HCC

  RestartResume

  Current Unmet Needs in the Field of Unresectable HCC

  MinuteCE®

  Current Unmet Needs in the Field of Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  RestartResume

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  MinuteCE®

  Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  RestartResume

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  MinuteCE®

  Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 program credit

• 

  RestartResume

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  RestartResume

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  MinuteCE®

  Empowering Treatment Choice: The Essential Role of Shared Decision-Making in Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  MinuteCE®

  WHIM Syndrome (A Chronic Neutropenic Disorder): Uncouple the Complex for HCPs and Patients

  1.00 credit 7 episodes

  • 

    

    Jolan Walter, MD, PHD

  • 

    

    Teresa K. Tarrant, MD

  • 

    

    Peter E. Newburger, MD

  • 

    

    Jacob R. Bledsoe, MD

  1.00 credit 7 episodes

• 

  RestartResume

  WHIM Syndrome: A Chronic Neutropenic Disorder

  RestartResume

  WHIM Syndrome: A Chronic Neutropenic Disorder

  MinuteCE®

  WHIM Syndrome: A Chronic Neutropenic Disorder

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  RestartResume

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  MinuteCE®

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  1.00 program credit

  • 

    

    Teresa K. Tarrant, MD

  1.00 program credit

• 

  RestartResume

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  RestartResume

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  MinuteCE®

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome Treatment: We Can Do Better!

  RestartResume

  WHIM Syndrome Treatment: We Can Do Better!

  MinuteCE®

  WHIM Syndrome Treatment: We Can Do Better!

  1.00 program credit

  • 

    

    Jolan Walter, MD, PHD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome Management: The First FDA Approval for Patients

  RestartResume

  WHIM Syndrome Management: The First FDA Approval for Patients

  MinuteCE®

  WHIM Syndrome Management: The First FDA Approval for Patients

  1.00 program credit

  • 

    

    Teresa K. Tarrant, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  RestartResume

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  MinuteCE®

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  1.00 program credit

  • 

    

    Jacob R. Bledsoe, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome: A Misguided Immune System!

  RestartResume

  WHIM Syndrome: A Misguided Immune System!

  MinuteCE®

  WHIM Syndrome: A Misguided Immune System!

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  MinuteCE®

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  MinuteCE®

  Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies

  1.25 credits 11 episodes

  • 

    

    Yelena Janjigian, MD

  • 

    

    Samuel J. Klempner, MD

  1.25 credits 11 episodes

• 

  RestartResume

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  RestartResume

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  MinuteCE®

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  RestartResume

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  RestartResume

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  MinuteCE®

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits